OpenEvidence Launches AI Telemedicine Platform
OpenEvidence has released its AI-integrated Doctor Dialer™ platform for telemedicine. The system provides a unified interface for doctor-patient calls, messaging, and voicemail with deeply integrated live clinical decision AI. A limited release of the suite has already powered approximately 37 million minutes of patient care communications in the U.S.
- The company was founded in 2022 by Daniel Nadler, whose previous AI analytics firm, Kensho, was acquired by S&P Global for $550 million in 2018. Nadler was reportedly motivated to start OpenEvidence after his grandfather passed away due to a medical error. - The new Doctor Dialer expands on OpenEvidence's core product, an AI-powered medical search engine that provides physicians with evidence-based answers from over 35 million peer-reviewed publications. The platform has achieved a 90 percent score on the United States Medical Licensing Examination (USMLE). - The AI provides real-time clinical decision support during patient calls and automatically generates evidence-based clinical notes from the conversation. The entire platform is designed to be HIPAA-compliant, meeting federal standards for the protection of sensitive patient health information. - OpenEvidence has seen rapid adoption, with over 40% of physicians in the United States using the platform as of July 2025. The company states that this year, one in three Americans will be treated by a physician using its technology. - Access to the platform, including the new Doctor Dialer feature, is offered at no cost to verified U.S. healthcare professionals. The company's growth has been driven by a direct-to-clinician model, with 95% of new users hearing about it from a colleague. - The company has established partnerships with several major medical organizations, including the American Medical Association, the New England Journal of Medicine (NEJM), and the JAMA Network. - In July 2025, OpenEvidence raised $210 million in a funding round led by GV (Google Ventures) and Kleiner Perkins, which valued the company at $3.5 billion.
